Probiotics: The benefits of bacterial cultures

Comprehensive Therapy

Volumn 31, Issue 3, 2005, Pages 181-185

  Macintyre, Ann ^a   Cymet, Tyler Childs ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; MESALAZINE; PROBIOTIC AGENT; SPOROBACTERIN; ULTRA LEVURE; UNCLASSIFIED DRUG; VANCOMYCIN;

ALLERGY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BIFIDOBACTERIUM; CANCER; CROHN DISEASE; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; ENDOCARDITIS; ENTERITIS; ENTEROCOCCUS; FUNGEMIA; HUMAN; ILEITIS; IMMUNITY; IMMUNOMODULATION; INFECTION PREVENTION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS FERMENTUM; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; NONHUMAN; OPPORTUNISTIC INFECTION; OTITIS MEDIA; SACCHAROMYCES BOULARDII; SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION; STREPTOCOCCUS; SURGICAL INFECTION; TONSILLITIS; UROGENITAL TRACT DISEASE; UROGENITAL TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS;

ANIMALS; DIARRHEA; FEMALE UROGENITAL DISEASES; GASTROINTESTINAL DISEASES; HUMANS; HYPERSENSITIVITY; INFECTION; MALE UROGENITAL DISEASES; NEOPLASMS; PROBIOTICS; VACCINES;

EID: 23844484922     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:31:3:181     Document Type: Article

References (47)

1. Food and Agriculture Organization, World Health Organization. Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria: Report of Joint FAO/WHO Expert Consultation. Rome, Italy: Food and Agriculture Organization; 2001.
2. Metchnikoff E. The Prolongation of Life. New York, NY: Putnam & Sons: 1908.
3. Silva M, Jacobus NV, Deneke C, et al. Antimicrobial substance from a human lactobacillus strain. Antimicrob Agents Chmother 1987;31:1231-1233.
4. Michail S, Wei S, Mack DR. Escherichia coli strain E2348/69 in vitro adhesion is reduced in the presence of a Lactobacillus species. Gastroenterology 1997;112:A1042.
5. Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human lactobacillus strain. Pediatr Res 1992;32:141-144.
6. Miettinem M, Matikainen S, Vuopio-Varkila J, et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood monocellular cells. Infect Immun 1998;66:6058-6062.
7. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002;109:678-684.
8. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002;47:2625-2634.
9. Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr 2003;36:112-115.
10. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999;104:e64.
11. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135:564-568.
12. McFarland LV, Surawicz CM, Greenberg RN. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-448.
13. Lewis SJ, Potts LF, Barry RE. J Infect 1998;36:171-174.
14. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-1918.
15. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-1017.
16. Attar A, Flourie B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117;794-797.
17. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-1464.
18. Kruis W, Schutz E, Fric P, et al. Aliment Pharmacol Ther 1997;11:853-858.
19. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639.
20. Gionchetti P, Rizzello F, Ventri A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.
21. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-169.
22. Wendakoon CN, Thomson ABR, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion 2002;65:16-20.
23. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginaitis. Ann Intern Med 1992;116:353-357.
24. Hilton E, Rindos P, Esenberg HD. Lactobacillus GG vaginal suppositories and vaginitis. J Clin Microbiol 1995;33:1433.
25. Hillier S. The vainal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 1998;14:S17-S21.
26. Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type I: possible role in heterosexual transmission. J Exp Med 1991;174:289-292.
27. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotic in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001;357:1076-1079.
28. Nikitensko VI. Infection prophylaxis of gunshot wounds using probiotics. J Wound Care 2004;13:363-366.
29. Nikitenko VI, Zakharov VV, Borodin AV, et al. Role of bacterial translocation in pathogenesis of surgical infection. Khirurgiia 2001;2:63-66.
30. Roos K, Holm SE, Grahn E, et al. Alpha-streptotocci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized plaebo-controlled study. Scand J Infect Dis 1993;25:31-35.
31. Roos K, Holm SE, Grahn, et al. Recolonization with four selecdted alpha-streptococcal strains in the treatment of recurrent streptococcal tonsillitis - a placebo-controlled randomized multicenter study. Scand J Infect Dis 1996;34:542-584.
32. Roos K, Grahn-Hakansson E, Holm S. Effect of recolonisation with "interfering" alpha-streptococci on recurrences of acute and secretory otitis media in children: randomized placebo controlled trial. BMJ 2001;322:210-212.
33. Gan BS, Kim J, Reid G, et al. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J Infect Dis 2002;185:1369-1372.
34. Rayes N, Hansen S, Seehofer D, et al. Early enteral supply of fiber and Lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 2002;18:609-615.
35. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002;74:123-127.
36. Anderson AD, McNaught CE, Jain PK, et al. Randomised clinical trial of symbiotic therapy in elective surgical patients. Gut 2004;53:241-245.
37. Lin-Amster H, Rochat F, Saudan KY, et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994;10:55-64.
38. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect 2000;2:681-686.
39. Aso Y, Akazan H. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. Urol Int 1992;49:125-129.
40. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double blind trial. The BLP Study Group. Eur Urol 1995;27:104-109.
41. Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999;28:930.
42. Presterl E, Kneifl W, Mayer HK, et al. Endocarditis by Lactobacillus rhamnosus due to yoghurt ingestion? Scand J Infect Dis 2001;33:710-714.
43. Mackay AD, Taylor MB, Kibbler CC, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:290-292.
44. Apostolou E, Kirjavainen P, Saxelin M, et al. Good adhesion properties of probiotics: a potential risk for bactermia? FEMS Immunol Med Microbiol 2001;31:35-39.
45. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from Lactobacillus rhamnosus strain GG. Clin Infect Dis 1999;28:1159-1160.
46. See endnote 100 in Potential uses of probiotics in clinical practice.
47. Weese, JS. Microbiologic evaluation of commercial probiotics. J Am Vet Med Assoc 2002;15:794-797.